ARNT (Aryl hydrocarbon receptor nuclear translocator) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target and a tumour suppressor, and an approved or late-stage drug is recorded against it. Tied to Skin cancer, Breast cancer, Small-cell lung cancer and 1 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transcription factor that functions as an obligate heterodimerisation partner for several basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) proteins. Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target gene promoters. Also heterodimerises with hypoxia-inducible factor alpha subunits (HIF1A, EPAS1, NPAS1 or NPAS3) to form hypoxia-inducible transcription factors that bind hypoxia response elements (HREs) and activate genes involved in cellular and systemic responses to hypoxia, including angiogenesis, erythropoiesis, and metabolic adaptation. Plays a central role in environmental sensing and developmental and physiological regulation of gene expression. Location: Nucleus (UniProt). Locus 1q21.3 (HGNC).
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.51 with breast cancer (MONDO_0007254)
- Small-cell lung cancer: IntOGen driver in 1 cohort (SCLC)
- Melanoma: Open Targets association 0.56 with melanoma (MONDO_0005105)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"ARNT" OR ABSTRACT:"ARNT" OR TITLE:"aryl hydrocarbon receptor nuclear translocator" OR ABSTRACT:"aryl hydrocarbon receptor nuclear translocator" OR TITLE:"Aryl hydrocarbon receptor nuclear translocator" OR ABSTRACT:"Aryl hydrocarbon receptor nuclear translocator" OR TITLE:"HIF1B" OR ABSTRACT:"HIF1B" OR TITLE:"HIF-1beta" OR ABSTRACT:"HIF-1beta" OR TITLE:"bHLHe2" OR ABSTRACT:"bHLHe2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARNT, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/arnt.json. Licence CC BY-NC 4.0.